Detalhe da pesquisa
1.
HIV-Tat immunization induces cross-clade neutralizing antibodies and CD4(+) T cell increases in antiretroviral-treated South African volunteers: a randomized phase II clinical trial.
Retrovirology
; 13(1): 34, 2016 Jun 09.
Artigo
Inglês
| MEDLINE | ID: mdl-27277839
2.
HIV-1 Tat immunization restores immune homeostasis and attacks the HAART-resistant blood HIV DNA: results of a randomized phase II exploratory clinical trial.
Retrovirology
; 12: 33, 2015 Apr 29.
Artigo
Inglês
| MEDLINE | ID: mdl-25924841
3.
The presence of anti-Tat antibodies in HIV-infected individuals is associated with containment of CD4+ T-cell decay and viral load, and with delay of disease progression: results of a 3-year cohort study.
Retrovirology
; 11: 49, 2014 Jun 24.
Artigo
Inglês
| MEDLINE | ID: mdl-24961156
4.
Anti-Tat immunity defines CD4+ T-cell dynamics in people living with HIV on long-term cART.
EBioMedicine
; 66: 103306, 2021 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-33839064
5.
Continued Decay of HIV Proviral DNA Upon Vaccination With HIV-1 Tat of Subjects on Long-Term ART: An 8-Year Follow-Up Study.
Front Immunol
; 10: 233, 2019.
Artigo
Inglês
| MEDLINE | ID: mdl-30815001
6.
Therapeutic immunization with HIV-1 Tat reduces immune activation and loss of regulatory T-cells and improves immune function in subjects on HAART.
PLoS One
; 5(11): e13540, 2010 Nov 11.
Artigo
Inglês
| MEDLINE | ID: mdl-21085635
7.
HIV-1 Tat-based vaccines: an overview and perspectives in the field of HIV/AIDS vaccine development.
Int Rev Immunol
; 28(5): 285-334, 2009.
Artigo
Inglês
| MEDLINE | ID: mdl-19811313
8.
Phase I therapeutic trial of the HIV-1 Tat protein and long term follow-up.
Vaccine
; 27(25-26): 3306-12, 2009 May 26.
Artigo
Inglês
| MEDLINE | ID: mdl-19208456
9.
The preventive phase I trial with the HIV-1 Tat-based vaccine.
Vaccine
; 28(2): 371-8, 2009 Dec 11.
Artigo
Inglês
| MEDLINE | ID: mdl-19879233